FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)
Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy treatment.
Signed written informed consent obtained prior to any study specific procedures.
Patient must be willing and able to comply with the protocol.
Age ≥ 18.
Known hypersensitivity to folic acid.
Use of prednisolone more than 10 mg daily.
Niels Fristrup
Lead sponsor
Aarhus University Hospital
Sponsor institution